Qian Xu, Ma Chenming, Nie Xiaobo, Lu Jianxin, Lenarz Minoo, Kaufmann Andreas M, Albers Andreas E
Key Laboratory of Laboratory Medicine, Ministry of Education, Zhejiang Provincial Key Laboratory of Medical Genetics, Wenzhou Medical University, Zhejiang, PR China; Department of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Department of Otorhinolaryngology, Head and Neck Surgery, Charité-Universitätsmedizin Berlin, Campus Benjamin Franklin, Berlin, Germany.
Crit Rev Oncol Hematol. 2015 Sep;95(3):337-45. doi: 10.1016/j.critrevonc.2015.03.009. Epub 2015 Apr 9.
Immunological approaches against tumors including head and neck squamous cell carcinoma (HNSCC) have been investigated for about 50 years. Such immunotherapeutic treatments are still not sufficiently effective for therapy of HNSCC. Despite the existence of immunosurveillance tumor cells may escape from the host immune system by a variety of mechanisms. Recent findings have indicated that cancer stem(-like) cells (CSCs) in HNSCC have the ability to reconstitute the heterogeneity of the bulk tumor and contribute to immunosuppression and resistance to current therapies. With regard to the CSC model, future immunotherapy possibly in combination with other modes of treatment should target this subpopulation specifically to reduce local recurrence and metastasis. In this review, we will summarize recent research findings on immunological features of CSCs and the potential of immune targeting of CSCs.
针对包括头颈部鳞状细胞癌（HNSCC）在内的肿瘤的免疫治疗方法已经研究了大约50年。这种免疫治疗对HNSCC的治疗仍然不够有效。尽管存在免疫监视，肿瘤细胞仍可能通过多种机制逃避免疫系统。最近的研究结果表明，HNSCC中的癌症干细胞（CSCs）能够重建实体瘤的异质性，并导致免疫抑制和对当前疗法的抗性。关于CSC模型，未来的免疫疗法可能与其他治疗模式联合，应专门针对该亚群以减少局部复发和转移。在这篇综述中，我们将总结关于CSCs免疫特征和CSCs免疫靶向潜力的最新研究结果。
